Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.
Bottom Line: Plasma levels of interleukin (IL)-17, IL-22, IL-23, IL-1β, IL-6, and transforming growth factor (TGF)-β1 were significantly increased in blood and bone marrow in AML patients compared with healthy donors.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.Show MeSH
Related in: MedlinePlus
Mentions: Interleukin-17 has been reported to reduce the production of IFN-γ in PBMCs stimulated with IL-12.(27) We therefore determined whether IL-17A and IL-22, two cytokines secreted by Th17 cells,(28) affect the generation and differentiation of Th1 cells in AML. Interleukin-17A and IL-22 significantly inhibited the IL-12-induced IFN-γ-producing cells in PBMCs isolated from healthy donors or AML patients (Fig. 5a,b). Furthermore, the production of IFN-γ was reduced in the presence of combination of IL-17A and IL-22 (Fig. 5c). The findings suggest that Th17 cells-associated cytokines down-regulate Th1 cell responses in AML patients.
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.